Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
The use of tantalum oxide nanoparticles in topical formulation for age related macular degeneration
Author Affiliations & Notes
  • Xinxin Zhao
    Institute of Molecular and Cell Biology, Singapore, Singapore
    National University of Singapore, Singapore, Singapore
  • Xinyi Su
    Institute of Molecular and Cell Biology, Singapore, Singapore
    National University of Singapore, Singapore, Singapore
  • Footnotes
    Commercial Relationships   Xinxin Zhao None; Xinyi Su None
  • Footnotes
    Support  AF-PP grant (OrBiTAl:Ocular Biomaterials for Vitreoretinal Therapeutic Applications; Grant number H20c6a0033) for generous funding support for this work
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6103. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xinxin Zhao, Xinyi Su; The use of tantalum oxide nanoparticles in topical formulation for age related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6103.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Nanoparticles are widely used as drug carriers to promote penetration, cellular uptaking and target delivery. Cerium oxide nanoparticles (CeO2-NPs, or nanoceria) have been used in eyedrop formulation because of its antioxidant activity. Their functions in AMD and retinitis pigmentosa and neuroprotective properties have been proved using animal models. In this work, we reported the potential application of another anti-oxidant inorganic nanoparticle, Tantalum (V) oxide, in terms of enhancing topical penetration of aflibercept and the corresponding anti-oxidative activity.

Methods : Method:
3 types of Tantalum oxide nanoparticles were tested in terms of biocompatiblity and anti-oxidative activity at the concentrations from 0.01-0.2 mg/m using corneal epithelial cells (CECs) and ARPE-19 cells. Lactate dehydrogenase (LDH) assay and DHF-DA assay were used for the evaluations.

Results : Tantalum oxide nanoparticles (TaOx-NPs) are biocompatible upto 100 ug/mL to CECs after 24 hours exposure. The presence of TaOx NPs significantly enhanced cellular uptake of aflibercept by CECs, which potentially promote ocular barrier penetration of aflibercept through intracellular path. The presence of TaOx NPs reduced the amount of reactive oxygen species (ROS) using ARPE-19 cells.

Conclusions : TaOx is a promising candidate for topical formulation, they are expected to promote the topical penetration of aflibercept and synergistically enlarge therapeutic effect through their intrinsic anti-ROS function.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×